Frontiers in Immunology | Cancer Immunity and Immunotherapy

Mini Review

Published on 13 May 2025

The promise of PD1/PDL1 targeted immunotherapy in locally advanced cervical cancer: a game-changer for patients outcome?

in Cancer Immunity and Immunotherapy

Fadila Kouhen
Adil El Ghanmi
Hanane Inghaoun
Hayat Miftah
Bouchra Ghazi
Abdallah Badou

Frontiers in Immunology

doi 10.3389/fimmu.2025.1573576

205 views

Original Research

Published on 13 May 2025

IL-6 is a prognostic biomarker in patients with advanced esophageal squamous cell carcinoma received with PD-1 inhibitors

in Cancer Immunity and Immunotherapy

Ping Huang
Manyi Zhao
Jianhong Xia
Hongliang Li
Junxia Sun
Xin Li
Chunsheng Yang
Guangyi Gao
Wenhang Zhou
Meifeng Zhong

Frontiers in Immunology

doi 10.3389/fimmu.2025.1569042

200 views

Original Research

Published on 13 May 2025

Cost-effectiveness analysis of first-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma

in Cancer Immunity and Immunotherapy

Zhifeng Zhou
Yanqing Yang
Shaofang Chen
Maojin You

Frontiers in Immunology

doi 10.3389/fimmu.2025.1575627

296 views

Original Research

Published on 13 May 2025

Potentiating T cell tumor targeting using a combination of TCR with a Siglec-7 based CSR

in Cancer Immunity and Immunotherapy

Shiran Didi-Zurinam
Erel Katzman
Cyrille J. Cohen

Frontiers in Immunology

doi 10.3389/fimmu.2025.1536868

144 views

Original Research

Published on 13 May 2025

HDAC6 inhibition by ITF3756 modulates PD-L1 expression and monocyte phenotype: insights for a promising immune checkpoint blockade co-treatment therapy

in Cancer Immunity and Immunotherapy

Valeria Spadotto
Chiara Ripamonti
Andrea Ghiroldi
Elisabetta Galbiati
Pietro Pozzi
Roberta Noberini
Tiziana Bonaldi
Christian Steinkühler
Gianluca Fossati

Frontiers in Immunology

doi 10.3389/fimmu.2025.1546939

377 views

Original Research

Published on 13 May 2025

Reversing VTN deficiency inhibits the progression of pancreatic cancer and enhances sensitivity to anti-PD1 immunotherapy

in Cancer Immunity and Immunotherapy

Siqi Zhao
Zhaofeng Gao
Lingyu Hu
Yihan Li
Xiaoguang Wang
Xiaoping Li
Minjie Chen
Fei Chen
Zhengwei Song

Frontiers in Immunology

doi 10.3389/fimmu.2025.1578870

261 views

Review

Published on 13 May 2025

Lactate-mediated metabolic reprogramming of tumor-associated macrophages: implications for tumor progression and therapeutic potential

in Cancer Immunity and Immunotherapy

Xiaohan Jin
Ni Zhang
Tinghao Yan
Jingyang Wei
Lingli Hao
Changgang Sun
Haibo Zhao
Shulong Jiang

Frontiers in Immunology

doi 10.3389/fimmu.2025.1573039

260 views

Original Research

Published on 13 May 2025

Prognostic significance of calcium-related genes in lung adenocarcinoma and the role of TNNC1 in macrophage polarization and erlotinib resistance

in Cancer Immunity and Immunotherapy

Jian Feng
Zhe Chen
Gaoming Wang
Yu Yao
Xuewen Min
Jing Luo
Kai Xie

Frontiers in Immunology

doi 10.3389/fimmu.2025.1509222

232 views

Systematic Review

Accepted on 12 May 2025

Global hotspots and trends in pre-metastatic niche research: A bibliometric analysis(2005-2024)

in Cancer Immunity and Immunotherapy

Mengqi Cheng
Qianhui Sun
Hua Duan
Cihui Chen

Frontiers in Immunology

doi 10.3389/fimmu.2025.1552053

Mini Review

Accepted on 12 May 2025

Roles and Functions of Tumor-Infiltrating Lymphocytes and Tertiary Lymphoid Structures in Gastric Cancer Progression

in Cancer Immunity and Immunotherapy

Zhiyuan Yao
Gengchen Li
Pan Di
Zichen Pei
Yan Fang
Haonan Liu
Zhengxiang Han

Frontiers in Immunology

doi 10.3389/fimmu.2025.1595070

Original Research

Accepted on 12 May 2025

Unraveling the role of GPCR signaling in metabolic reprogramming and immune microenvironment of lung adenocarcinoma: A Multi-Omics Study with experimental validation

in Cancer Immunity and Immunotherapy

Zhaoxuan Wang
Cheng Wang
Shilei Zhao
Chundong Gu

Frontiers in Immunology

doi 10.3389/fimmu.2025.1606125

Editorial

Accepted on 12 May 2025

Editorial: Harnessing Single-Cell Insights: Pioneering Predictive Markers for Immunotherapy Efficacy in Solid Tumors

in Cancer Immunity and Immunotherapy

Zhongbao Zhou

Frontiers in Immunology

doi 10.3389/fimmu.2025.1625920

Original Research

Accepted on 12 May 2025

Integrated Multi-Omics Analysis and Experimental Investigation of Mitochondrial Dynamics-Related Genes: Molecular Subtypes, Immune Landscape, and Prognostic Implications in Lung Adenocarcinoma

in Cancer Immunity and Immunotherapy

Sixuan Wu
Junfan Pan
Lijun Zeng
Qihong Pan
Yao Yu
Jincan Lin
Jing Zhang
Yiling Jiang

Frontiers in Immunology

doi 10.3389/fimmu.2025.1585505

Correction

Accepted on 12 May 2025

Corrigendum: Characterization of TLR9 responsiveness in cell subsets derived from in vitro pDC differentiation of hematopoietic stem and progenitor cells

in Cancer Immunity and Immunotherapy

Sabina Sanchez Hernandez
Tobias Wang Bjerg
Ian Helstrup Nielsen
Anders Laustsen
Hai Q Tang
Lars Henning Pedersen
Eynav Klechevsky
Martin R. Jakobsen
Rasmus O Bak

Frontiers in Immunology

doi 10.3389/fimmu.2025.1625107

Mini Review

Accepted on 12 May 2025

T Lymphocyte Heterogeneity in NSCLC: Implications for Biomarker Development and Therapeutic Innovation

in Cancer Immunity and Immunotherapy

Yu Liu
Denghui Qin
Jiejun Fu

Frontiers in Immunology

doi 10.3389/fimmu.2025.1604310

158 views

Original Research

Accepted on 12 May 2025

Radiation therapy for intestinal barrier damage and repair process -Differences in salivary metabolites and non-invasive monitoring of intestinal barrier function

in Cancer Immunity and Immunotherapy

Jingjing Zhang
Kun Wang
Yanyu Qiao
Mengjie Zhang
Yunqing Chen
Yulong Tian
Xuelong Jiao
Xiaojie Tan
Haitao Jiang
Feng Hou

Frontiers in Immunology

doi 10.3389/fimmu.2025.1590219